相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis
Gauri Mishra et al.
JOURNAL OF GASTROINTESTINAL CANCER (2023)
Immunotherapy for hepatocellular carcinoma
Mingzhen Zhou et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2023)
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function
Giuseppe Cabibbo et al.
DIGESTIVE AND LIVER DISEASE (2022)
Risk of hepatocellular carcinoma after hepatitis C virus cure
Maria Alejandra Luna-Cuadros et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2022)
Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review
Manon Falette Puisieux et al.
CANCERS (2022)
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
Carmelo Laface et al.
CANCERS (2022)
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Soojin Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
The changing scenario of hepatocellular carcinoma in Italy: an update
Francesca Garuti et al.
LIVER INTERNATIONAL (2021)
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study
Margherita Rimini et al.
HEPATOLOGY RESEARCH (2021)
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
Valentina Burgio et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib
Marie Decraecker et al.
CANCERS (2021)
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Yuan-Hung Kuo et al.
FRONTIERS IN ONCOLOGY (2021)
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
M. Rimini et al.
ESMO OPEN (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
Tetsu Tomonari et al.
JGH OPEN (2021)
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib
Toshifumi Tada et al.
SCIENTIFIC REPORTS (2021)
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
Atsushi Hiraoka et al.
SCIENTIFIC REPORTS (2021)
Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study
Takeshi Hatanaka et al.
ONCOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
Antonio Facciorusso et al.
CANCERS (2020)
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Mohamed A. Abd El Aziz et al.
VACCINES (2020)
Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review
Laura Llamosas-Falcon et al.
SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY (2020)
Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis
Masahito Nakano et al.
HEPATOLOGY COMMUNICATIONS (2020)
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Atsushi Hiraoka et al.
HEPATOLOGY RESEARCH (2019)
The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
Shuntaro Obi et al.
HEPATOLOGY INTERNATIONAL (2019)
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis
Atsushi Hiraoka et al.
CANCER MEDICINE (2019)
Marginal Time-Dependent Causal Effects in Mediation Analysis With Survival Data
Francesca Fasanelli et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Hepatocellular Carcinoma Is Diagnosed at a Later Stage in Alcoholic Patients: Results of a Prospective, Nationwide Study
Charlotte E. Costentin et al.
CANCER (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Impact of smoking habit on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma
Keita Kai et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Viral hepatitis and hepatocellular carcinoma: etiology and management
Philippe J. Zamor et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma
Francesca Romana Ponziani et al.
LIVER INTERNATIONAL (2016)
Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases
Antonio Facciorusso et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Trends in the management and burden of alcoholic liver disease
Philippe Mathurin et al.
JOURNAL OF HEPATOLOGY (2015)
CURRENT CONCEPTS Hepatocellular Carcinoma
Hashem B. El-Serag
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)